Original Research
Accepted on 26 Aug 2025
Subcutaneous foslevodopa/foscarbidopa initiation in a Parkinson's day-clinic -a suitable setting to ensure treatment efficacy, tolerability and psychosocial adaption
in Parkinson’s Disease and Aging-related Movement Disorders